Realm Therapeutics (RLM) is developing a pipeline of novel topical treatments for highly prevalent dermatology indications using its proprietary stabilised hypochlorous acid (HOCl) technology. RLM is investigating the potential already seen in its preclinical studies with topical HOCl formulations to date. They suggest immunomodulatory activity alongside well-documented safety evidence: an encouraging base from which to potentially deliver efficacious and safer alternatives to first line therapies.
24 May 2018
On track for Atopic Dermatitis readout in Q3
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
On track for Atopic Dermatitis readout in Q3
Realm Therapeutics (RLM:LON) | 0 0 0.3% | Mkt Cap: 57.1m
- Published:
24 May 2018 -
Author:
Emma Ulker -
Pages:
3
Realm Therapeutics (RLM) is developing a pipeline of novel topical treatments for highly prevalent dermatology indications using its proprietary stabilised hypochlorous acid (HOCl) technology. RLM is investigating the potential already seen in its preclinical studies with topical HOCl formulations to date. They suggest immunomodulatory activity alongside well-documented safety evidence: an encouraging base from which to potentially deliver efficacious and safer alternatives to first line therapies.